上海凯鑫(300899) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was CNY 227,925,969.91, representing a 20.42% increase compared to CNY 189,276,783.70 in 2020[19]. - The net profit attributable to shareholders for 2021 was CNY 48,063,431.51, a 9.54% increase from CNY 43,876,177.33 in 2020[19]. - The net cash flow from operating activities surged to CNY 45,976,975.90, a significant increase of 7,102.34% compared to CNY 638,362.05 in 2020[19]. - The basic earnings per share for 2021 was CNY 0.7535, down 11.01% from CNY 0.8467 in 2020[19]. - The total assets at the end of 2021 amounted to CNY 709,261,984.75, reflecting a 2.83% increase from CNY 689,775,637.15 at the end of 2020[19]. - The company achieved a revenue of 228 million yuan in 2021, representing a year-on-year growth of 20.42%[47]. - The gross profit margin was 37.33%, a decrease of 0.75% compared to the previous year[47]. - The net profit attributable to shareholders was 48.06 million yuan, an increase of 9.54% year-on-year[47]. - The total assets at the end of the reporting period were 709.26 million yuan, up 2.83% from the end of the previous year[47]. Market and Industry Outlook - The membrane separation technology industry in China is expected to grow at an average annual rate of 20%, with a target market value of CNY 2,500 billion to CNY 3,000 billion by the end of the 13th Five-Year Plan[29]. - The total market value of China's membrane industry is projected to exceed CNY 3,600 billion by 2022, indicating robust growth potential[29]. - The government has set a target for industrial water reuse rate to reach approximately 94% by 2025, with specific increases in high-water-consuming industries like steel and petrochemicals[35]. - By 2025, the total capacity for seawater desalination in China is expected to exceed 2.9 million tons per day, with a significant portion of this growth driven by coastal cities[34]. - The company is one of the few in China providing comprehensive membrane separation technology solutions in the industrial fluid sector, significantly contributing to environmental protection and economic value[37]. Research and Development - The company’s R&D expenditure accounted for 7.41% of its operating income, with R&D personnel making up 29.79% of total employees[43]. - The company has obtained 48 patent certificates, reflecting its continuous investment in technology and innovation[43]. - R&D investment reached ¥16,881,969.98, a 45.53% increase from the previous year, constituting 7.41% of operating revenue[53]. - The company has completed the research on membrane combination technology for industrial waste salt recovery, aiming to provide a more economically viable solution for high-salinity wastewater treatment, which is expected to significantly enhance economic benefits and alleviate environmental pressures[60]. - The company is focusing on the green production of antibiotics, optimizing the extraction and purification processes to reduce production costs and carbon emissions, thereby enhancing competitiveness[61]. Corporate Governance - The company has established a robust corporate governance structure, ensuring compliance with relevant laws and regulations, and maintaining independence from its controlling shareholders[113]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced and compliant governance framework[114]. - The company has implemented a comprehensive information disclosure system to ensure timely and accurate communication with investors, enhancing transparency[115]. - The company maintains an independent operational structure, with distinct R&D, procurement, production, and sales systems, ensuring autonomy in business operations[117]. - The company has established a complete and independent financial accounting department, ensuring independent financial decision-making and tax compliance[118]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[5]. - The company acknowledges the risk of increased competition in the membrane separation industry, necessitating ongoing investment in technology and new business areas[105]. - The company is implementing measures to manage accounts receivable risks, including evaluating customer credit ratings and enhancing collection efforts[107]. - The company faces risks related to fluctuations in gross margin due to customized pricing models and increasing overseas import-export activities, which may be affected by exchange rate volatility[108]. - The company emphasizes the importance of retaining technical talent, as the loss of skilled personnel could significantly impact its sustainable development; strategies include improving employee benefits and enhancing recruitment efforts[109]. Shareholder Relations and Dividends - The company reported a cash dividend of 3.30 RMB per 10 shares for a total of 63,783,466 shares, with no bonus shares issued[5]. - The total distributable profit for the company as of December 31, 2021, was 177,509,907.45 yuan, which is the basis for the profit distribution plan[151]. - The company proposed a cash dividend of 3.30 yuan per 10 shares (including tax), amounting to a total cash dividend of 21,048,543.78 yuan, representing 100% of the total distributable profit[148][151]. - The company’s cash dividend distribution accounted for 100% of the total distributable profit, indicating a strong commitment to returning value to shareholders[148]. - The company has committed to ensuring that there are no fraudulent activities in the public offering of shares, with a promise to buy back shares if any fraudulent issuance is confirmed by regulatory authorities[182]. Financial Management - The company raised a total of RMB 38,965.85 million through its public offering, with a net amount of RMB 35,292.19 million after deducting issuance costs of RMB 3,673.66 million[79]. - The company has a cash management strategy that includes RMB 10,800 million in bank financial products that have not yet matured[79]. - The company reported a net decrease in cash and cash equivalents of ¥84,307,179.04, a decline of 123.96% compared to an increase of ¥351,929,114.42 in 2020[65]. - The company’s long-term equity investments reached ¥15,109,226.47, representing 2.13% of total assets, a new addition for the year[70]. - The company’s cash balance in the special account for raised funds is RMB 16,803.77 million, including net interest income of RMB 403.26 million[79]. Employee and Talent Development - The company emphasizes the importance of talent development, establishing a comprehensive training system and optimizing the talent structure to enhance operational efficiency[99]. - The total number of employees at the end of the reporting period was 94, with 69 in the parent company and 25 in major subsidiaries[144]. - The professional composition includes 39 production personnel, 9 sales personnel, 28 technical personnel, 9 financial personnel, and 9 administrative personnel[145]. - The educational background of employees shows 17 with master's degrees or above, 46 with bachelor's degrees, and 31 with associate degrees or below[145]. - The company has implemented employee incentive policies to create a healthy and harmonious work environment[167].